Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Receivables - Net (2020 - 2025)

Historic Receivables - Net for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $258000.0.

  • Insight Molecular Diagnostics' Receivables - Net rose 2344.5% to $258000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $258000.0, marking a year-over-year increase of 2344.5%. This contributed to the annual value of $1.6 million for FY2024, which is 23326.45% up from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Receivables - Net stood at $258000.0, which was up 2344.5% from $512000.0 recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Receivables - Net ranged from a high of $3.5 million in Q1 2025 and a low of $85000.0 during Q2 2024
  • Its 5-year average for Receivables - Net is $1.1 million, with a median of $1.0 million in 2021.
  • Its Receivables - Net has fluctuated over the past 5 years, first surged by 530769.23% in 2021, then plummeted by 8850.0% in 2024.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Receivables - Net stood at $1.4 million in 2021, then decreased by 2.57% to $1.4 million in 2022, then crashed by 65.43% to $484000.0 in 2023, then skyrocketed by 233.26% to $1.6 million in 2024, then tumbled by 84.0% to $258000.0 in 2025.
  • Its Receivables - Net stands at $258000.0 for Q3 2025, versus $512000.0 for Q2 2025 and $3.5 million for Q1 2025.